A new SNP assay was successfully developed and validated for the identification of the Ala67Thr polymorphism in the human PVR/CD155 gene, enabling large-scale screening.
Answers are grounded in this paper and cite their sources.
Validated assay enables large-scale CD155 screening; leaves open clinical relevance pending further studies.
BACKGROUND & OBJECTIVES: It is important to understand the role of cell surface receptors in susceptibility to infectious diseases. CD155 a member of the immunoglobulin super family, serves as the poliovirus receptor (PVR). Heterozygous (Ala67Thr) polymorphism in CD155 has been suggested as a risk factor for paralytic outcome of poliovirus infection. The present study pertains to the development of a screening test to detect the single nucleotide (SNP) polymorphism in the CD155 gene. METHODS: New primers were designed for PCR, sequencing and SNP analysis of Exon2 of CD155 gene. DNAs extracted from either whole blood (n=75) or cells from oral cavity (n=75) were used for standardization and validation of the SNP assay. DNA sequencing was used as the gold standard method. RESULTS: A new SNP assay for detection of heterozygous Ala67Thr genotype was developed and validated by testing 150 DNA samples. Heterozygous CD155 was detected in 27.33 per cent (41/150) of DNA samples tested by both SNP detection assay and sequencing. INTERPRETATION & CONCLUSIONS: The SNP detection assay was successfully developed for identification of Ala67Thr polymorphism in human PVR/CD155 gene. The SNP assay will be useful for large scale screening of DNA samples.
No takes yet. Share an insight, caveat, or question.
Nandi et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: